Search Within

Linda Su Hyun Ahn

  1. "American Society of Clinical Oncology"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (1)
Groups
  1. Department of Medicine (9)
  2. Nursing (9)
  3. Solid Tumor Oncology Division (9)
  4. Thoracic Oncology (8)
  5. GSK Faculty (7)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (6)

More Groups

People
  1. Charles Rudin (5)
  2. Helena Yu (4)
  3. Mark Kris (4)
  4. Paul Paik (4)
  5. Andrew Plodkowski (3)
  6. Gregory Riely (3)

More People

Years
  1. 2024 (2)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (2)
  5. 2018 (2)
  6. 2010 (1)
Publications
  1. Journal of Clinical Oncology (8)
  2. JCO Precision Oncology (1)
Publishers
  1. American Society of Clinical Oncology (9)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations
    Meeting Abstract

    Chen, M. F.; Rakhade, S.; Quintanal-Villalonga, A.; Lee, J.; Forsythe, B.; Moses, K. A.; Ahn, L. S. H.; Pupo, A.; Falcon, C. J.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor
    Journal Article

    Luo, J.; Makhnin, A.; Tobi, Y.; Ahn, L.; Hayes, S. A.; Iqbal, A.; Ng, K.; Arcila, M. E.; Riely, G. J.; Kris, M. G.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Plodkowski, A. J.; Fan, P. D.; Rudin, C. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Ginsberg, M. S.; Plodkowski, A. J.; Kim, R.; Doyle, L. A.; Rudin, C. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed PD-L1 IHC low/unknown stage IV squamous cell lung cancers
    Meeting Abstract

    Paik, P. K.; Srikakulum, A.; Ahn, L. S. H.; Plodkowski, A. J.; Ng, K. K.; McFarland, D.; Fiore, J. J.; Iqbal, A.; Eng, J.; Rudin, C. M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228
    Meeting Abstract

    Paik, P. K.; Qeriqi, B.; Ahn, L. S. H.; Ginsberg, M. S.; Tandon, N.; McFarland, D.; Doyle, L. A.; de Stanchina, E.; Rudin, C. M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF)
    Meeting Abstract

    Gounder, M. M.; Antonescu, C.; Hameed, M. R.; D'Adamo, D. R.; Keohan, M.; Singer, S.; Brennan, M. F.; Ahn, L. S.; Maki, R. G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save